NCT02136914 - ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

DyskinesiaLevodopa Induced Dyskinesia (LID)Parkinson's Disease

Interventions

DRUG

ADS-5102

Oral capsules to be administered once nightly at bedtime, for 25 weeks

OTHER

Placebo

Oral capsules to be administered once nightly at bedtime, for 25 weeks

Trial Locations (46)

10003

New York

10016

New York

10029

New York

11725

Commack

12208

Albany

19107

Philadelphia

27607

Raleigh

30329

Atlanta

32607

Gainesville

33331

Weston

33351

Sunrise

33486

Boca Raton

33613

Tampa

33980

Port Charlotte

34102

Naples

35233

Birmingham

43614

Toledo

44195

Cleveland

45219

Cincinnati

48025

Bingham Farms

48322

West Bloomfield

50309

Des Moines

53233

Milwaukee

55427

Golden Valley

60612

Chicago

63110

St Louis

66160

Kansas City

74136

Tulsa

75390

Dallas

80045

Aurora

85013

Phoenix

85259

Scottsdale

85351

Sun City

90505

Torrance

91105

Pasadena

91335

Reseda

92708

Fountain Valley

93003

Ventura

95817

Sacramento

98034

Kirkland

06040

Manchester

77030-1

Houston

77030-2

Houston

T6G 2B7

Edmonton

M5T 2S8

Toronto

S4T 1A5

Regina